SynthesisAnnals of internal medicine2015
Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis.
Synthesis in Annals of internal medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Regular versus as-needed treatments for mild asthma in children, adolescents, and adults: a systematic review and network meta-analysis.BMC medicine · 2025Pooled it
- Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2023Pooled it
- The relationship between obstructive sleep apnea and asthma severity and vice versa: a systematic review and meta-analysis.European journal of medical research · 2023Pooled it
- Breaking the bottleneck of asthma treatment: the future of omni-targeted therapy.Journal of advanced research · 2026Review
- Molecular insights into ago-allosteric modulation at cysteinyl leukotriene receptor 2.Nature communications · 2025Article
- Expert opinion on gray areas in asthma management: A lesson from the innovative project "revolution in asthma" of the Italian thoracic society (AIPO-ITS).Clinical and translational allergy · 2025Review
- Stepwise Approach in Asthma Revisited 2023: Expert Panel Opinion of Turkish Guideline of Asthma Diagnosis and Management Group.Thoracic research and practice · 2023Article
- Questions in Mild Asthma: An Official American Thoracic Society Research Statement.American journal of respiratory and critical care medicine · 2023Article
- A Current Perspective of Allergic Asthma: From Mechanisms to Management.Handbook of experimental pharmacology · 2022Review
- Prescription rate and treatment patterns for allergic rhinitis from 2010 to 2018 in South Korea: a retrospective study.Clinical and molecular allergy : CMA · 2021Article
- Recent Insights into the Management of Inflammation in Asthma.Journal of inflammation research · 2021Review
- Structure-Based Virtual Screening of Ultra-Large Library Yields Potent Antagonists for a Lipid GPCR.Biomolecules · 2020Article
- Role of Montelukast as Monotherapy in Improving Quality of Life of an Asthmatic Patient in Pakistan.Cureus · 2020Article
- Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors.Nature communications · 2019Article
- Prevalence of Montelukast Use as an Add-On Therapy among Iraqi Asthmatics on Treatment Attending Al-Kindy Teaching Hospital and Al-Zahraa Center of Asthma and Allergy.Open access Macedonian journal of medical sciences · 2019Article
- The Role of Leukotrienes as Potential Therapeutic Targets in Allergic Disorders.International journal of molecular sciences · 2019Review
- Article
- Effectiveness and Quality of Life with Montelukast in Asthma - A double-blind randomized control trial.Pakistan journal of medical sciences · 2019Article
- The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.European journal of clinical pharmacology · 2017Review
- Lipid Mediators of Allergic Disease: Pathways, Treatments, and Emerging Therapeutic Targets.Current allergy and asthma reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundLeukotriene-receptor antagonists (LTRAs) are recommended as an alternative treatment in patients with mild asthma, but their effect compared with placebo is unclear. PURPOSE: To determine the benefits and harms of LTRAs as monotherapy or in combination with inhaled corticosteroids compared with placebo in adults and adolescents with asthma. DATA SOURCES: MEDLINE and the Cochrane Central Register of Controlled Trials from inception through June 2015. STUDY SELECTION: Peer-reviewed, English-language, randomized, controlled trials in patients with asthma that reported the effect of LTRAs versus placebo on measures of asthma control. DATA EXTRACTION: Three researchers extracted data on study population, interventions, outcome measures, and adverse events. One researcher assessed risk of bias. DATA SYNTHESIS: Of the 2008 abstracts that were screened, 50 trials met eligibility criteria. Random-effects meta-analyses of 6 trials of LTRA monotherapy showed that LTRAs reduced the risk for an exacerbation (summary risk ratio [RR], 0.60 [95% CI, 0.44 to 0.81]). In 4 trials of LTRAs as add-on therapy to inhaled corticosteroids, the summary RR for exacerbation was 0.80 (CI, 0.60 to 1.07). Leukotriene-receptor antagonists either as monotherapy or as add-on therapy to inhaled corticosteroids increased FEV1, whereas FEV1 percentage of predicted values was improved only in trials of LTRA monotherapy. Adverse event rates were similar in the intervention and comparator groups. LIMITATION: Variation in definitions and reporting of outcomes, high risk of bias in some studies, heterogeneity of findings, possible selective outcome reporting bias, and inability to assess the effect of asthma severity on summary estimates.
conclusionLeukotriene-receptor antagonists as monotherapy improved asthma control compared with placebo, but which patients are most likely to respond to treatment with LTRAs remains unclear. PRIMARY FUNDING SOURCE: National Institutes of Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.